Objectives: Although more women living with HIV (WLWH) are entering midlife, the experiences of perimenopausal and menopausal WLWH, including the effects of menopausal symptoms severity, remain understudied. This study longitudinally investigated the correlates of antiretroviral therapy (ART) adherence among perimenopausal and menopausal WLWH from Metro Vancouver.
G
lobally, approximately 17.8 million women are living with HIV, comprising 51% of adults living with HIV. 1 In Canada, women constitute approximately a quarter of people living with HIV (PLWH). 2 Echoing global trends, the survival of Canadian women living with HIV (WLWH) has improved significantly after the expansion of antiretroviral therapy (ART), 3 with more WLWH now entering the age of perimenopause and menopause (between 45 and 56 years of age). 4 Moreover, adult women constitute the majority of new infections among Canadian women, with 64% of new HIV infections being amongst women aged 30þ, according to 2014 estimates. 2 With a growing number of WLWH entering their mid-life, there is a need to better understand the challenges related to menopause among WLWH, including the impact of menopause on the clinical management of HIV.
Given that, until recently, WLWH did not live long enough to experience menopause; this is a relatively new phenomenon and remains a neglected area of study. 5 However, emergent research suggests there may be key differences in the experiences of perimenopause and menopause based on HIV status. [5] [6] [7] Though data are conflicting, 4 and the age range of reaching menopause is broad, in general, some evidence suggests that WLWH are reaching menopause at earlier ages (ranging from 47.5 to 50 years, versus an average of 51 years [40-58] among Canadian women not living with HIV), 5, 6, [8] [9] [10] with smoking, substance use, and coinfection with hepatitis C, CD4 count <50 cells/mm 3 associated with earlier menopause. 9, 11, 12 Other studies suggest that menopausal symptoms may be more prevalent and severe among WLWH, though again, data are mixed. 10, 13, 14 Among the menopausal symptoms that women experience, vasomotor symptoms (ie, night sweats, hot flashes, and flushes) have been the most researched, and linked to increased levels of depression. 10 The role of urogenital (eg, sexual complaints, vaginal dryness, urinary complaints) or psychological symptoms (eg, irritability, anxiety, feelings of sadness, fatigue) in the context of HIV are less well-known, including how menopausal symptoms may collectively affect HIV clinical outcomes or disease progression among WLWH. Additionally, the structural challenges and barriers to the clinical management of HIV among perimenopausal and menopausal women are not well-known, with existing studies rarely disaggregating perimenopausal and menopausal WLWH from other WLWH. It is likely that menopausal WLWH experience unique barriers to their health and well-being, which may exacerbate challenges experienced in the menopause transition.
Despite the importance of menopause for the health and quality of life for women, there remains a dearth of studies examining how menopause, particularly the severity of menopausal symptoms, impacts the HIV cascade of care among women. 5 While some studies have hypothesized the link between the prevalence of menopausal symptoms and reduced ART adherence, 10, 15 our literature review located only one study examining this association. 16 This study, by Maki et al, 16 focused on depressive symptoms among menopausal WLWH and found elevated depressive symptoms to reduce ART adherence. To our knowledge, there are no studies examining how the severity of menopausal symptoms collectively affect ART adherence.
Given the growing number of WLWH entering the age of menopause, and the knowledge gap surrounding the impact of menopause and related symptoms on the HIV treatment adherence, this study sought to examine the correlates of suboptimal ART adherence (defined as <95% adherence) among menopausal WLWH in Metro Vancouver, including the impact of menopausal symptom severity, using the standardized and validated menopausal rating scale (MRS). We hypothesize that illicit drug use and increased menopausal symptom severity will be associated with suboptimal ART adherence.
METHODS

Study design and sampling
Our analysis drew on data from an ongoing communitybased, longitudinal study, known as Sexual Health and HIV/AIDS: Women's Longitudinal Needs Assessment (SHAWNA) (2014 till present). SHAWNA is a partnership of more than 20 women's HIV and community service providers, guided by a Community Stakeholder Advisory Board that meets semi-annually, and a Positive Women's Advisory Board of WLWH from Metro Vancouver, that meets every 2 to 3 months. The SHAWNA study was developed based on over 6 months of community consultations with WLWH, HIV care providers, and policy experts, with the aim to longitudinally assess the needs and priorities identified in women living with and accessing care in HIV (WLWH) in Metro Vancouver.
Study eligibility includes being a WLWH (trans inclusive), aged 14 17 which has been used among several populations, including WLWH. 10, 18 Participants also receive voluntary viral load/CD4 measurements and Sexually Transmitted Infections/Hepatitis C Virus serology by one of the project's sexual health nurses. If needed, project nurses offer onsite treatment for symptomatic STI infections and Papanicolaou testing (regardless of enrollment in the study), and facilitate education support and referrals. At each visit, participants receive $50 CAD remuneration for their time, expertise, and travel. The study holds ethical approval through Providence Health Care/University of British Columbia Research Ethics Board and BC Women's Hospital.
Primary outcome
The primary outcome, self-reported suboptimal ART adherence, was based on participants' estimates of their adherence to ART being <95% versus 95% in the past 3 to 4 weeks, and is a time-updated measure. Suboptimal ART adherence, defined as <95% self-reported adherence in the past 3 to 4 weeks, was employed as it has been found to be an DUFF ET AL accurate measure of adherence (highly correlated to pill count and HIV viral load), 19 and has been used in previous studies among WLWH in Canada. 20 Explanatory variables were selected based on their a priori known relationship with ART adherence, particularly among older WLWH. Sociodemographic variables examined were: age (measured continuously, in years); sexual orientation (ie, identifying as gay, lesbian, bisexual, asexual or two-spirit vs straight, at baseline); ethnicity (defined as Indigenous [First Nations, Métis, or Inuit] vs White vs African/Caribbean/ Black); and education (defined as high-school graduate vs less than high school). All the sociodemographic variables listed above were considered time-independent variables. The remaining individual, social, and structural variables were considered time-dependent and updated to refer to occurrences in the previous 6 months. Individual variables considered included injection and noninjection drug use. Having had a mental health diagnosis (lifetime, time-updated for at least one of many mental health conditions: eg, depression, anxiety, post-traumatic stress disorder, schizophrenia, attention deficit disorder, borderline personality disorder, bipolar disorder), and duration of HIV infection (continuous, in years) and MRS were time-updated measures asked by the research nurse to support education, referral, and support. The MRS was used to capture the severity of menopausal symptoms, and refer to symptoms experienced at the time of the interview. The MRS consists of 11 items and includes three symptom domains: somatic symptoms (eg, sweating/hot flushes, cardiac complaints, sleeping disorders, joint, and muscle complaints), urogenital symptoms (eg, vaginal dryness, sexual problems, urinary complaints), and psychological symptoms (eg, depressive mood, anxiety, irritability, and exhaustion). Participants rated the severity of symptoms on a 5-point scale, from none (scored as 0), to extremely severe (4). A total score was calculated by summing the ratings for each symptom with possible scores ranging from asymptomatic (for a score of 0) to the highest degree of symptom complaints (score of 44). The MRS scale has a high internal consistency, with a Cronbach alpha of 0.90 for the full scale. 21 The following time-updated interpersonal and structural variables were also examined: experienced gender-based physical and/or sexual violence, homelessness, sex work, and being incarcerated (jail or prison overnight or longer).
Statistical analyses
Our sample was restricted to cis-gender women, 30 years of age or older, who had ever been diagnosed by a healthcare provider as perimenopausal or menopausal, or self-reported that they were experiencing perimenopause or menopause. While menopause among the general population is often defined as amenorrhea for >12 months, we did not use this definition, as menstrual irregularity, anovulation, and amenorrhea are common among WLWH, and can confound the ability to accurately assess menopause. 6, 22 Menopause/perimenopause diagnosis by a physician was based on a ''yes'' response to the question: ''Have you ever been told by a doctor that you have menopause or perimenopause?'' Selfdefined menopause was defined as an answer of ''Yes'' to the question ''Do you feel that you may be experiencing menopause or perimenopause?'' When administering this question, interviewers described perimenopause/menopause and asked follow-up questions about symptoms including: the absence of a period for over a year, hot flashes, fatigue, chills, night sweats. Women who have had a hysterectomy were also excluded, as amenorrhea resulting from this procedure may also be mistakenly interpreted as menopause in self-report.
Descriptive statistics calculated included frequencies and proportions for categorical variables, and measures of central tendencies (ie, mean, medians, and interquartile ranges [IQRs]) for continuous data. Bivariate logistic regression with generalized estimating equations (GEEs), and an exchangeable correlation structure and logit link was first conducted to screen for independent associations of individual, social, and structural factors with adherence among perimenopausal and menopausal women. Pearson's chi-square tests (or Fisher's exact test for small cell counts) were used for categorical variables and Wilcoxon rank-sum test for continuous variables. GEE methods were employed to account for the timevarying variables in our analysis and adjusts the standard error to account for correlations arising from repeated measurements on the same participants over time. All 233 interviews were analyzed together using generalized estimating questions to account for multiple observations on the same participant. To measure the strength of association between categorical variables, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
Based on existing studies, 23,24 a P value cut-off of <0.10 was used to consider a priori hypothesized confounders for inclusion in the multivariable model. A backward stepwise approach was then used to construct the final multivariable model, beginning with a full model, followed by the removal of variables starting with the highest P value and an assessment of the quasi-likelihood under the independence model criterion (QIC) after the removal of each subsequent variable. The QIC value provides an indication of the combination of variables that best explain the variability in our outcome, adherence. The final model presented is the one exhibiting the lowest QIC value. The final model was tested for multicollinearity. All P values were two-sided, and SAS software version 9.4 was used for all statistical analyses (SAS Institute Inc., Cary, NC).
RESULTS
In total, longitudinal data for 109 perimenopausal and menopausal WLWH were included in this sample, for a total of 233 observations. The median number of interviews completed in this open cohort was two (IQR 1-3), with 70 participants completing more than one interview. Among the 70 participants who completed more than one interview, the median follow-up time was 12.4 months (IQR 6.5-17.3 months). The median age of our sample was 49 years (44-53), with the median age of perimenopause/menopause being MENOPAUSE AND REDUCED HIV TREATMENT ADHERENCE approximately 44.5 (IQR 40.5-49.0), based on the year that participants first experienced symptoms. The majority (56.0%) of our sample were Indigenous, with 36.7% White and 7.3% African/Caribbean/Black (ACB). At baseline, 13/ 109 (11.9%) participants indicated they had been offered treatment for menopause or perimenopausal symptoms.
The mean score for the full MRS was 10.90, with a median of 11 . Of the full sample, 71.6% had experienced any menopausal symptoms over the course of the study. Somatic symptoms were most common, experienced by 70.6% of participants, followed by psychological symptoms (65.1%) and urogenital symptoms (57.8%). In terms of severity, psychological symptoms were among the most severe, particularly physical and mental exhaustion, and irritability; 40% and 37.6%, respectively, rated these symptoms as moderately to extremely severe. Hot flashes were the most severely experienced somatic symptom, with 40.4% rating their hot flash symptoms as moderately to extremely severe. The median, and IQR and GEE bivariate associations of each domain of the MRS with ART adherence are presented in Table 1 .
Over the 2-year study period, 70.6% reported <95% ART adherence, with injection drug use (OR 3.04, 95% CI 1.62-6.00), gender-based physical/sexual violence (OR 2.72, 95% CI 1.23-6.00), Indigeneity (OR 2.22, 95% CI 1.03-4.77), and more severe menopausal symptoms (OR 1.03, 95% CI 1.00-1.05) significantly inversely associated with <95% adherence at P < 0.05 in bivariate GEE analysis. Age was found to decrease the odds of <95% adherence by 5% with every year increase (OR 0.95, 95% CI 0.91-1.00) ( Table 2) . 
DUFF ET AL
In our final multivariable GEE model, severe menopausal symptoms (measured continuously, using the MRS scale) (adjusted OR [AOR] 1.03, 95% CI 1.00-1.06), injection drug use (AOR 2.86, 95% CI 1.44-5.55), and physical/sexual gender-based violence (AOR 2.33, 95% CI 1.02-5.26) were inversely associated with <95% versus 95% adherence in our final model (at P < 0.05) ( Table 3) .
DISCUSSION
The marginal association between MRS and adherence in our data suggests that severe menopausal symptoms may be negatively associated with ART adherence. Suboptimal adherence to ART among perimenopausal and menopausal WLWH may be exacerbated by intersecting vulnerabilities, including physical/sexual violence and injection drug use. These data highlight the critical need to properly assess perimenopause and menopausal symptoms among WLWH, and offer treatment for these symptoms to improve WLWHs' quality of life and support optimal treatment adherence and outcomes. At present, properly identifying menopause can be challenging, with many physicians unaware that WLWH may experience early menopause and therefore not test folliclestimulating hormone (FSH) levels in younger WLWH to confirm menopause.
Our findings build on the limited information on the impact of menopause on the HIV cascade of care, and extend research that has hypothesized a link between menopause symptom severity and ART adherence. 10 Specifically, Looby et al 10 documented that WLWH with severe hot flash symptoms (measured using the MRS) had more challenges with daily activities and a reduced quality of life, and postulated that this destabilization of well-being could be negatively associated with ART adherence. Maki et al 16 have found adherence to be a predictor of depressive symptoms among menopausal WLWH. Others have hypothesized that the potential negative impact of depressive symptoms on ART adherence may place WLWH at increased risk of AIDSdefining illnesses. 15 Adding to previous research, our findings suggest that the combination of menopausal symptoms, rather than specific symptoms, may be negatively associated with WLWH's ability to adhere to ART. Aligned with previous research, it is possible that the challenges of managing menopausal symptoms and subsequent negative impact on WLWH's well-being may make adherence challenging. 10, 15, 16 Alternatively, WLWH may mistake menopausal symptoms for ART side-effects, 8 and it is possible that they may temporarily abandon treatment to alleviate their symptoms, though further investigation into this potential mechanism is warranted. There is a need to provide WLWH with education (by health providers and peer support groups/ navigators) around aging with HIV and menopausal symptoms, both to prepare women, and alleviate the stigma and fear around aging with HIV.
Among our sample, psychological and somatic symptoms were more common compared with urogenital complaints, with psychological symptoms (eg, irritability, mental, and physical exhaustion) being among the most severe symptoms experienced. It is important to mention, however, the high level of mental health comorbidities in our sample (ie, anxiety and depression) may contribute to the level of menopauserelated psychological symptoms reported. The severity of symptoms in our sample were slightly lower compared with other cohorts of WLWH and women in the general population that have also used MRS. For example, the mean score for the full MRS scale in our sample was 10.9 (median 11; IQR 0-19), compared with 15 among WLWH in the United States. 10 Similarly, among midlife American women enrolled in methadone maintenance therapy, the mean MRS score for the sample was 17.04 (SD 9.18). 25 These data suggest that the menopausal symptoms of WLWH in our sample may be lower compared with women in the general population, contradicting some existing literature that menopausal symptoms are more frequent and severe in WLWH. 10, 13, 14 The high level of engagement in care among our sample (eg, free ART, high levels of adherence, and greater access to support services and mental health treatment) compared with WLWH in other settings may contribute to the reduced severity of symptoms documented in our study. Whereas it is possible that WLWH in our sample do not experience more severe menopause, alternative explanations for this difference could include the earlier age of menopause among our sample, the older median age of our sample (49 years), combined with the fact that menopausal symptoms are often heightened in the early stages of perimenopause. Furthermore, previous research suggests menopausal symptoms are often underreported by WLWH, as they may attribute their symptoms to ART side-effects or other illnesses. 8 This may be particularly true of our sample of marginalized WLWH, who often contend with numerous overlapping vulnerabilities (eg, homelessness, violence and trauma, illicit drug use, mental health issues) and comorbidities (eg, hepatitis C, sexually transmitted infections). While our sample reported less severe symptoms compared to other cohorts/populations, the marginally significant association between increased symptoms severity and reduced ART adherence may be important.
The role of injection drug use, and to a lesser extent, physical and sexual violence, has been linked to reduced ART adherence and viral suppression among WLWH in various settings. [26] [27] [28] [29] [30] Unfortunately, our findings suggest that these barriers persist among mid-life WLWH and continue to undermine ART adherence. Given the complex interactions between HIV, ageing, and these social and structural factors, it is imperative that healthcare providers adopt a womencentred, trauma-informed approach to care, which acknowledges and addresses the broader social and structural factors (eg, violence, trauma, addictions) that interact to disrupt WLWH's ART adherence. This needs to be coupled with an expansion of and increased referrals/access to evidencebased addictions treatment.
Additionally, our findings highlight an urgent need to better assess for menopausal symptoms and offer treatment for menopausal symptoms among WLWH as a way to improve the quality of life of perimenopausal and menopausal WLWH, and also bolster ART adherence. Our data indicate that very few (11.9%) perimenopausal and menopausal WLHW in our sample were offered treatment for their menopausal symptoms, with only 6 (5.5%) women reporting being on HT at baseline. This low use of HT echoes trends elsewhere, 5 and are comparable with estimates among menopausal women in the general Canadian population (4.9%). 31 There remains a general lack of data on effective strategies to manage menopause among WLWH, including the safety and efficacy of HT among WLWH, such as potential interactions with ART. 5 Further research is needed to better understand the risk and benefits of various management strategies for perimenopausal and menopausal WLWH. This study has a number of limitations. Firstly, the association between the MRS score and adherence includes 1, indicating only marginal significance. Secondly, our sample was restricted to perimenopausal and menopausal women, based on a physician's diagnosis or self-report. Since it is unclear how perimenopause and menopause was diagnosed (eg, FSH tests vs assessment of amenorrhea >12 months, or other symptoms), it is possible that our sample may also include premenopausal women, which could potentially underestimate the age of menopause and severity of menopausal symptoms. A study from Cejtin et al 22 suggests that many WLWH with prolonged amenorrhea were not menopausal when diagnosed using FSH blood tests. However, given the older median age of our sample, we suspect this limitation to be minimal. Third, WLWH may mistakenly attribute their menopausal symptoms to ART side-effects or other health ailments that would result in an under-reporting of menopausal symptoms. Fourth, while more than half of our sample were Indigenous, and were less likely to be adherent compared with other ethnicities, we did not examine differences in the severity of menopausal symptoms by ethnicity. Future analyses into the differences in age of menopause and severity of symptoms by ethnicity are warranted. Fifth, given the small sample size and the relatively large number of variables examined, it is possible that significant associations detected were due to these multiple comparisons. Additionally, this study's small sample size may lack the power to detect associations, thus missing potential risk factors for ART adherence. However, the multiple observations for each participant in this cohort study increases the total number of observations, tempering these biases. Finally, our outcome (95% adherence) may be susceptible to social desirability bias, resulting in an over-reporting of adherence. However, we have no reason to believe that women experiencing more severe menopausal symptoms would differentially report adherence levels. The community-based nature of this study, which uses highly trained peer-research associates (including women living with HIV) who have a strong rapport with the community of WLWH, likely tempers the impact of social desirability bias on our adherence measure.
CONCLUSIONS
In summary, our findings suggest that increased severity of menopausal symptoms may be associated with lower ART adherence among perimenopausal and menopausal WLWH, and this may be exacerbated by intersecting vulnerabilities, including injection drug use and recent sexual/physical violence. With WLWH aging, there is a higher need to more accurately identify and treat menopausal symptoms, in the context of women-centred and trauma-informed care. Care needs to address the numerous and overlapping social and structural barriers to adherence (eg, violence-related trauma, addictions, and depression) and provides active DUFF ET AL referrals to complementing/supporting health and social services, including trauma counseling and evidence-based harm reduction services. Further research is needed to identify effective strategies for managing menopause and related symptoms among WLWH, to improve adherence and their quality of life.
